About Nugenic Pharma Private Limited
Data last updated: 06 January 2026
Nugenic Pharma Private Limited is a private limited company based in Baddi, Himachal Pradesh, India. It specialises in pharmaceutical packaging solutions, a part of the broader packaging sector. Incorporated on 09 December 2004, the company has been in operation for over 22 years.
Registered with ROC Himachal Pradesh under CIN U24230HP2004PTC027717.
Capital: an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.87 Cr. It is led by directors including Manoj Kumar Lohariwala and Vinay Kumar Lohariwala.
Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: 69/A Epip Phase – 1 Jharmajri, Baddi, Himachal Pradesh, India – 173205.
As per the financials filed for FY 2025, the company reported a revenue of ₹79.17 Cr, a decline of 2% compared to the previous year.
The company has a workforce of approximately 232 employees as per the latest available data.
The company is associated with 1 brand - Innova Captab. As per MCA filings, the company has open charges of ₹25.2 Cr and satisfied charges of ₹6.78 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website innovacaptab.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address69/A Epip Phase – 1 Jharmajri, Baddi, Himachal Pradesh, India – 173205
-
IndustryPackaging, Pharmaceutical Packaging Solutions
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Nugenic Pharma Private Limited
Nugenic Pharma Private Limited operates one associated brand: Innova Captab. These brands represent Nugenic Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are manufactured by Innova Captab as a CDMO. | innovacaptab.com |
Competitors & Alternatives of Nugenic Pharma Private Limited
Brands and companies operating in the same space as Nugenic Pharma Private Limited include Pharmaron, Pfizer, Lonza and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Pharmaron
|
Drug discovery and development services for small molecules are provided. | Beijing, China, China | 2003 |
Pfizer
|
Pharmaceutical products for treating multiple diseases are provided. | New York, United States, United States | 1849 |
Lonza
|
CDMO services for pharma, biotech, and specialty ingredients are provided. | Basel, Switzerland, Switzerland | 1897 |
Dotmatics
|
AI powered scientific data management and workflow automation solutions | - | 2005 |
Boehringer Ingelheim
|
Generic drugs and clinical research services are provided globally. | - | 1885 |
LabConnect
|
Laboratory testing, clinical trial research, and biopharma services are provided. | Johnson City, United States, United States | 2002 |
Beta Drugs
|
Developer of therapeutics for oncology and dermatology | Panchkula, India, India | 2005 |
Ainos
|
Novel point-of-care testing and low-dose interferon therapeutics are developed. | San Diego, United States, United States | 1986 |
Biomatter
|
Provider of synthetic biology and AI-based technology for generative protein design | Vilnius, Lithuania, Lithuania | 2018 |
Business Activity of Nugenic Pharma Private Limited
Nugenic Pharma Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including wood and wood products, furniture, paper and paper products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C3 | Wood and wood products, furniture, paper and paper products | ********* |
Auditor Details of Nugenic Pharma Private Limited
Nugenic Pharma Private Limited is audited by GARG SANJEEV & ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| GARG SANJEEV & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Nugenic Pharma Private Limited
Nugenic Pharma Private Limited is currently managed by 4 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manoj Kumar Lohariwala | Director | 09 Dec 2004 | 21 Years 7 Months | Current |
| Vinay Kumar Lohariwala | Director | 09 Dec 2004 | 21 Years 7 Months | Current |
|
Rohit Lohariwala
Also directs:
Innoventis Medicare Limited
|
Director | 20 Mar 2014 | 12 Years 3 Months | Current |
|
Rahul Luhariwala
Also directs:
Innoventis Medicare Limited
|
Director | 21 Oct 2021 | 4 Years 8 Months | Current |
Financials of Nugenic Pharma Private Limited FY 2025 filings available
Nugenic Pharma Private Limited reported revenue of ₹79.17 Cr (down 2% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Nugenic Pharma Private Limited
As of FY 2023, Nugenic Pharma Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Nugenic Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Oct 2020 | Yes Bank Limited | ₹25.2 Cr | Open |
| 01 Nov 2011 | State Bank of India | ₹4.58 Cr | Satisfied |
| 25 Feb 2011 | Axis Bank Ltd. | ₹2.2 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Nugenic Pharma Private Limited
Nugenic Pharma Private Limited has a workforce of 232 employees as of Apr 09, 2024.
Employee Count & EPFO Data of Nugenic Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nugenic Pharma Private Limited
GSTIN & GST Filing Data of Nugenic Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nugenic Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nugenic Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nugenic Pharma Private Limited
MSME Payment Delays by Nugenic Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nugenic Pharma Private Limited
Subsidiaries & Group Companies of Nugenic Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nugenic Pharma Private Limited with ownership details.
MCA Filings & Documents of Nugenic Pharma Private Limited
MCA Filings & Documents of Nugenic Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nugenic Pharma Private Limited
Frequently Asked Questions about Nugenic Pharma Private Limited
Nugenic Pharma Private Limited is an active private limited company in the packaging sector based in Baddi, Himachal Pradesh, India. It was incorporated on 09 December 2004 (22+ years old) and is registered under CIN U24230HP2004PTC027717. The company has 232 employees.
Nugenic Pharma Private Limited reported revenue of ₹79.17 Cr for FY 2025 (down 2.00% YoY).
The current directors of Nugenic Pharma Private Limited are:
The primary industry of Nugenic Pharma Private Limited is packaging. The company specifically operates in pharmaceutical packaging solutions. The company is currently active in this sector.
Nugenic Pharma Private Limited can be reached at the registered office: 69A Epip Phase – 1 Jharmajri, Baddi, Himachal Pradesh, India – 173205, or through the website innovacaptab.com.
The authorised capital is ₹2 Cr, and the paid-up capital is ₹1.87 Cr.